Unknown

Dataset Information

0

Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.


ABSTRACT: Chromodomain, helicase, DNA binding 5 (CHD5) is a member of a subclass of the chromatin remodeling Swi/Snf proteins and has recently been proposed as a tumor suppressor in a diverse range of human cancers. We analyzed all 41 coding exons of CHD5 for somatic mutations in 123 primary ovarian cancers as well as 60 primary breast cancers using high-resolution melt analysis. We also examined methylation of the CHD5 promoter in 48 ovarian cancer samples by methylation-specific single-stranded conformation polymorphism and bisulfite sequencing. In contrast to previous studies, no mutations were identified in the breast cancers, but somatic heterozygous missense mutations were identified in 3 of 123 ovarian cancers. We identified promoter methylation in 3 of 45 samples with normal CHD5 and in 2 of 3 samples with CHD5 mutation, suggesting these tumors may have biallelic inactivation of CHD5. Hemizygous copy number loss at CHD5 occurred in 6 of 85 samples as assessed by single nucleotide polymorphism array. Tumors with CHD5 mutation or methylation were more likely to have mutation of KRAS or BRAF (P = .04). The aggregate frequency of CHD5 haploinsufficiency or inactivation is 16.2% in ovarian cancer. Thus, CHD5 may play a role as a tumor suppressor gene in ovarian cancer; however, it is likely that there is another target of the frequent copy number neutral loss of heterozygosity observed at 1p36.

SUBMITTER: Gorringe KL 

PROVIDER: S-EPMC2570601 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.

Gorringe Kylie L KL   Choong David Yh DY   Williams Louise H LH   Ramakrishna Manasa M   Sridhar Anita A   Qiu Wen W   Bearfoot Jennifer L JL   Campbell Ian G IG  

Neoplasia (New York, N.Y.) 20081101 11


Chromodomain, helicase, DNA binding 5 (CHD5) is a member of a subclass of the chromatin remodeling Swi/Snf proteins and has recently been proposed as a tumor suppressor in a diverse range of human cancers. We analyzed all 41 coding exons of CHD5 for somatic mutations in 123 primary ovarian cancers as well as 60 primary breast cancers using high-resolution melt analysis. We also examined methylation of the CHD5 promoter in 48 ovarian cancer samples by methylation-specific single-stranded conforma  ...[more]

Similar Datasets

| S-EPMC2834558 | biostudies-literature
| S-EPMC3446335 | biostudies-literature
| S-EPMC4657932 | biostudies-literature
| S-EPMC4390162 | biostudies-literature
| S-EPMC7331373 | biostudies-literature
| S-EPMC3234930 | biostudies-literature
| S-EPMC2648865 | biostudies-literature
| S-EPMC8798113 | biostudies-literature
| S-EPMC4471293 | biostudies-literature
2021-02-12 | GSE146398 | GEO